CRL · 8-K · 20261109PR017127

Acquisition / Partnership / Divestiture

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-09 · Importance 71 · Surprise 60 · Contradicted

Charles River agreed to acquire Frontage Holdings’ bioanalysis and DMPK businesses in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in contingent performance payments; closing is expected in the first half of 2027, subject to approvals and customary conditions. The businesses generated approximately 40% of Frontage’s 2025 revenue of $256.7 million, or about $103 million, and are expected to grow at the projected bioanalysis sector rate over the next five years. The transaction is expected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter, with acquisition-related costs excluded from that measure. Charles River expects to finance the purchase price and associated fees through its credit facility and available cash; the acquired businesses will be reported in the DSA segment and include two Exton sites totaling approximately 150,000 square feet and approximately 340 employees.

Key facts

• The acquisition purchase price is approximately $470 million in cash, subject to customary closing adjustments. source
• The transaction includes additional payments of up to $75 million contingent on future performance of the acquired businesses. source
• The acquisition is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals and other customary closing conditions. source
• The acquired bioanalysis and DMPK businesses represented approximately 40% of Frontage’s total 2025 revenue of $256.7 million. source
• On November 9, 2026, Charles River announced definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania. source
• Charles River is participating in a consortium with Hongkong Tigermed Co., Limited and Dr. Song Li to privatize Frontage, after which Charles River will ultimately own the assets and liabilities related to Frontage’s bioanalysis and DMPK businesses in Exton, Pennsylvania. source
• Charles River, Frontage’s controlling shareholder Tigermed, and Frontage Chairman Dr. Song Li formed a consortium and acquisition vehicle to privatize Frontage by a court-sanctioned scheme of arrangement, after which Frontage’s listing will be withdrawn. source
• Immediately after privatization, the parties plan to separate Frontage’s businesses into subsidiaries; Charles River will retain the bioanalysis and DMPK businesses through sole ownership of the acquisition vehicle and certain Frontage subsidiaries, while Frontage’s remaining businesses will be transferred to Tigermed and Dr. Song Li or his affiliates. source

Impact estimates